IDEXX Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, he… Read more
IDEXX Laboratories Inc (IDXX) - Net Assets
Latest net assets as of December 2025: $1.61 Billion USD
Based on the latest financial reports, IDEXX Laboratories Inc (IDXX) has net assets worth $1.61 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.35 Billion) and total liabilities ($1.75 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.61 Billion |
| % of Total Assets | 47.91% |
| Annual Growth Rate | 12.26% |
| 5-Year Change | 132.67% |
| 10-Year Change | N/A |
| Growth Volatility | 73.44 |
IDEXX Laboratories Inc - Net Assets Trend (1991–2025)
This chart illustrates how IDEXX Laboratories Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IDEXX Laboratories Inc (1991–2025)
The table below shows the annual net assets of IDEXX Laboratories Inc from 1991 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.61 Billion | +0.63% |
| 2024-12-31 | $1.60 Billion | +7.46% |
| 2023-12-31 | $1.48 Billion | +143.87% |
| 2022-12-31 | $608.74 Million | -11.78% |
| 2021-12-31 | $689.99 Million | +9.04% |
| 2020-12-31 | $632.79 Million | +255.85% |
| 2019-12-31 | $177.82 Million | +2025.97% |
| 2018-12-31 | $-9.23 Million | +82.85% |
| 2017-12-31 | $-53.84 Million | +50.24% |
| 2016-12-31 | $-108.21 Million | -28.83% |
| 2015-12-31 | $-84.00 Million | -171.43% |
| 2014-12-31 | $117.59 Million | -77.31% |
| 2013-12-31 | $518.21 Million | -18.55% |
| 2012-12-31 | $636.26 Million | +17.91% |
| 2011-12-31 | $539.59 Million | -6.04% |
| 2010-12-31 | $574.28 Million | +11.60% |
| 2009-12-31 | $514.58 Million | +17.43% |
| 2008-12-31 | $438.19 Million | -0.03% |
| 2007-12-31 | $438.32 Million | +6.94% |
| 2006-12-31 | $409.86 Million | +10.98% |
| 2005-12-31 | $369.31 Million | -7.13% |
| 2004-12-31 | $397.66 Million | -3.78% |
| 2003-12-31 | $413.29 Million | +21.21% |
| 2002-12-31 | $340.97 Million | +13.01% |
| 2001-12-31 | $301.73 Million | +15.28% |
| 2000-12-31 | $261.75 Million | -7.93% |
| 1999-12-31 | $284.30 Million | -7.63% |
| 1998-12-31 | $307.80 Million | +1.68% |
| 1997-12-31 | $302.70 Million | -6.20% |
| 1996-12-31 | $322.70 Million | +15.62% |
| 1995-12-31 | $279.10 Million | +179.66% |
| 1994-12-31 | $99.80 Million | +19.38% |
| 1993-12-31 | $83.60 Million | +18.75% |
| 1992-12-31 | $70.40 Million | +123.49% |
| 1991-12-31 | $31.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IDEXX Laboratories Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 450000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $1.61 Billion | 100.00% |
| Total Equity | $1.61 Billion | 100.00% |
IDEXX Laboratories Inc Competitors by Market Cap
The table below lists competitors of IDEXX Laboratories Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kroger Company
NYSE:KR
|
$46.45 Billion |
|
Reckitt Benckiser Group PLC
PINK:RBGPF
|
$46.53 Billion |
|
Teradyne Inc
NASDAQ:TER
|
$46.56 Billion |
|
Apollo Global Management LLC Class A
NYSE:APO
|
$46.80 Billion |
|
Shin-Etsu Chemical Co. Ltd
PINK:SHECF
|
$46.17 Billion |
|
WW Grainger Inc
NYSE:GWW
|
$46.14 Billion |
|
Macquarie Group Limited
PINK:MCQEF
|
$46.05 Billion |
|
KDDI Corp PK
PINK:KDDIY
|
$45.75 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IDEXX Laboratories Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,595,313,000 to 1,605,383,000, a change of 10,070,000 (0.6%).
- Net income of 1,059,464,000 contributed positively to equity growth.
- Share repurchases of 1,216,964,000 reduced equity.
- Other comprehensive income increased equity by 93,645,000.
- Other factors increased equity by 73,925,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.06 Billion | +65.99% |
| Share Repurchases | $1.22 Billion | -75.81% |
| Other Comprehensive Income | $93.64 Million | +5.83% |
| Other Changes | $73.92 Million | +4.6% |
| Total Change | $- | 0.63% |
Book Value vs Market Value Analysis
This analysis compares IDEXX Laboratories Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 29.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1489.19x to 29.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1991-12-31 | $0.39 | $586.37 | x |
| 1992-12-31 | $0.66 | $586.37 | x |
| 1993-12-31 | $0.62 | $586.37 | x |
| 1994-12-31 | $0.75 | $586.37 | x |
| 1995-12-31 | $1.98 | $586.37 | x |
| 1996-12-31 | $2.05 | $586.37 | x |
| 1997-12-31 | $2.01 | $586.37 | x |
| 1998-12-31 | $2.03 | $586.37 | x |
| 1999-12-31 | $1.79 | $586.37 | x |
| 2000-12-31 | $1.81 | $586.37 | x |
| 2001-12-31 | $2.18 | $586.37 | x |
| 2002-12-31 | $2.43 | $586.37 | x |
| 2003-12-31 | $2.88 | $586.37 | x |
| 2004-12-31 | $2.78 | $586.37 | x |
| 2005-12-31 | $2.71 | $586.37 | x |
| 2006-12-31 | $3.11 | $586.37 | x |
| 2007-12-31 | $3.40 | $586.37 | x |
| 2008-12-31 | $3.52 | $586.37 | x |
| 2009-12-31 | $4.24 | $586.37 | x |
| 2010-12-31 | $4.82 | $586.37 | x |
| 2011-12-31 | $4.63 | $586.37 | x |
| 2012-12-31 | $5.66 | $586.37 | x |
| 2013-12-31 | $4.80 | $586.37 | x |
| 2014-12-31 | $1.16 | $586.37 | x |
| 2015-12-31 | $-0.90 | $586.37 | x |
| 2016-12-31 | $-1.19 | $586.37 | x |
| 2017-12-31 | $-0.60 | $586.37 | x |
| 2018-12-31 | $-0.11 | $586.37 | x |
| 2019-12-31 | $2.03 | $586.37 | x |
| 2020-12-31 | $7.29 | $586.37 | x |
| 2021-12-31 | $7.97 | $586.37 | x |
| 2022-12-31 | $7.20 | $586.37 | x |
| 2023-12-31 | $17.68 | $586.37 | x |
| 2024-12-31 | $19.21 | $586.37 | x |
| 2025-12-31 | $19.90 | $586.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IDEXX Laboratories Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 65.99%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.62%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 2.09x
- Recent ROE (65.99%) is above the historical average (35.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1991 | 10.16% | 10.49% | 0.80x | 1.21x | $50.00K |
| 1992 | 6.96% | 8.49% | 0.72x | 1.13x | $-2.14 Million |
| 1993 | 11.60% | 10.42% | 0.95x | 1.17x | $1.34 Million |
| 1994 | 13.33% | 10.52% | 1.04x | 1.22x | $3.32 Million |
| 1995 | 7.70% | 11.40% | 0.60x | 1.12x | $-6.41 Million |
| 1996 | 10.10% | 12.18% | 0.72x | 1.16x | $330.00K |
| 1997 | -6.97% | -8.02% | 0.70x | 1.25x | $-51.37 Million |
| 1998 | -4.94% | -4.75% | 0.82x | 1.27x | $-45.98 Million |
| 1999 | 11.47% | 9.15% | 0.99x | 1.27x | $4.17 Million |
| 2000 | 14.00% | 9.97% | 1.09x | 1.28x | $10.46 Million |
| 2001 | 12.47% | 9.74% | 1.03x | 1.24x | $7.45 Million |
| 2002 | 13.31% | 11.00% | 0.99x | 1.22x | $11.29 Million |
| 2003 | 13.81% | 11.99% | 0.91x | 1.26x | $15.76 Million |
| 2004 | 19.70% | 14.26% | 1.07x | 1.29x | $38.57 Million |
| 2005 | 21.21% | 12.26% | 1.30x | 1.33x | $41.35 Million |
| 2006 | 22.86% | 12.67% | 1.32x | 1.37x | $52.69 Million |
| 2007 | 21.45% | 10.19% | 1.31x | 1.60x | $50.18 Million |
| 2008 | 26.51% | 11.34% | 1.34x | 1.75x | $72.35 Million |
| 2009 | 23.75% | 11.85% | 1.28x | 1.57x | $70.77 Million |
| 2010 | 24.60% | 12.80% | 1.23x | 1.56x | $83.86 Million |
| 2011 | 29.98% | 13.28% | 1.18x | 1.91x | $107.83 Million |
| 2012 | 28.02% | 13.78% | 1.17x | 1.73x | $114.64 Million |
| 2013 | 36.24% | 13.64% | 1.12x | 2.37x | $135.98 Million |
| 2014 | 154.79% | 12.24% | 1.07x | 11.78x | $170.15 Million |
| 2015 | 0.00% | 11.99% | 1.09x | 0.00x | $200.49 Million |
| 2016 | 0.00% | 12.51% | 1.16x | 0.00x | $232.88 Million |
| 2017 | 0.00% | 13.36% | 1.15x | 0.00x | $268.55 Million |
| 2018 | 0.00% | 17.04% | 1.44x | 0.00x | $377.98 Million |
| 2019 | 241.01% | 17.77% | 1.31x | 10.33x | $409.97 Million |
| 2020 | 92.04% | 21.49% | 1.18x | 3.63x | $518.57 Million |
| 2021 | 107.95% | 23.17% | 1.32x | 3.53x | $675.85 Million |
| 2022 | 111.56% | 20.17% | 1.23x | 4.51x | $618.22 Million |
| 2023 | 56.92% | 23.08% | 1.12x | 2.20x | $696.59 Million |
| 2024 | 55.65% | 22.78% | 1.18x | 2.06x | $728.34 Million |
| 2025 | 65.99% | 24.62% | 1.28x | 2.09x | $898.93 Million |
Industry Comparison
This section compares IDEXX Laboratories Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $482,684,274
- Average return on equity (ROE) among peers: -68.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IDEXX Laboratories Inc (IDXX) | $1.61 Billion | 10.16% | 1.09x | $46.34 Billion |
| Agilent Technologies Inc (A) | $4.16 Billion | 9.64% | 0.80x | $31.54 Billion |
| Amer Bio Medica (ABMC) | $2.66 Million | -28.23% | 1.26x | $3.55K |
| ADCNF (ADCNF) | $852.85 Million | 37.00% | 2.65x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $2.00 Million |
| ANGLE plc (ANPCF) | $3.82 Million | -94.09% | 0.43x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.29K |
| Avricore Health Inc (AVCRF) | $-37.20K | 0.00% | 0.00x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $3.76 Million | -397.87% | 1.13x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $52.50 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $5.08 Million |